Gilead’s remdesivir study fails to show benefit for Covid-19 patients

Gilead’s remdesivir study fails to show benefit for Covid-19 patients

According to results from a clinical trial conducted in China Gilead, the antiviral medicine remdesivir has failed to speed the improvement of patients with Covid-19 or prevent death. Although the data does suggest potential benefit, incase of early stage treatment. A summary of the study results was accidentally posted to the website of the WHO and seen by STAT on Thursday, but later removed.

Milan
Milan
John Keller
John Keller 0 months

Best to wait for the peer review. Too many things can invalidate a study. It would be interesting to see how they set it up.

Rocky
Rocky 0 months

Not good. This was the most promising medication currently in trials. This will set back predicted treatments hitting the market by months at least.

Top in World
Get the App